NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, fisogatinib specifically binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase and is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:fibroblast growth factor receptor 4 inhibitor BLU-554
Code name:BLU 554
CS 3008
Chemical structure:
  • 2-propenamide, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2H-pyran-4-yl)-
  • N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide